In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Positive progression-free survival results in breast cancer for the company’s lead asset, margetuximab, take the markets by surprise.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
The €300m deal is in part a high-stakes bid to take on Merck & Co's Keytruda in lung cancer.
A deal between J&J and Meiragtx in eye disease shows growing interest from big pharma as gene therapy's commercial issues come into focus.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…